Eisai launches at-home Leqembi injection for early Alzheimer’s, reducing clinic visits.

Eisai has launched Leqembi Iqlik, a weekly subcutaneous injection of lecanemab-irmb, in the U.S. as a maintenance treatment for early Alzheimer’s disease. After 18 months of initial IV therapy, patients may switch to the at-home autoinjector option, marking the first anti-amyloid therapy to offer this choice. The new option aims to reduce clinic visits, improve access, and support ongoing treatment to maintain benefits. A companion program provides financial and educational support, including an app and injection tracking.